Search

Displaying results 8101 - 8110 of 10000 in total
  1. Drug

    Belinostat

    go.drugbank.com/drugs/DB05015
    ApprovedInvestigational

    Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. … It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic IndexSynonyms: (2E)-N-HYDROXY-3-(3-(PHENYLSULFAMOYL)PHENYL)PROP-2-ENAMIDE, 2-PROPENAMIDE, N-HYDROXY-3-(3-((PHENYLAMINO)SULFONYL)PHENYL)-
  2. Drug

    ATL1101

    go.drugbank.com/drugs/DB05023
    Experimental

    ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis. … ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis.

  3. Drug

    Lancovutide

    go.drugbank.com/drugs/DB05029
    Investigational

    Lancovutide, a peptide antibiotic, is in clinical development for the treatment of cystic fibrosis. … Lantibiotics are bacteriocins that are characterized by the presence of a high proportion of unusual amino acids.

  4. Drug

    Votucalis

    go.drugbank.com/drugs/DB05032
    Investigational

    It is a topically delivered small protein that acts as an anti-inflammatory agent.

  5. Drug

    INCB7839

    go.drugbank.com/drugs/DB05033
    Investigational

    INCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. … It represents a potentially important new class of targeted breast cancer therapy. It has shown promising clinical activity in heavily pretreated, refractory breast cancer patients.

  6. Drug

    Ularitide

    go.drugbank.com/drugs/DB05034
    Investigational

    Ularitide is currently in Phase 2 development as a potential treatment for patients with acute decompensated heart failure (ADHF). … Ularitide is a synthetic form of urodilatin, a naturally occurring human natriuretic peptide that is involved in regulating blood pressure and the excretion of water and sodium from the kidneys.

  7. Drug

    Eprotirome

    go.drugbank.com/drugs/DB05035
    Investigational

    Eprotirome which is a compound with promising properties for treatment of obesity and dyslipidemia.

  8. Drug

    SGS518

    go.drugbank.com/drugs/DB05042
    Experimental

    SGS518, a novel antagonist for the 5HT6 subtype of the serotonin receptor, is being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS).

  9. Drug

    Milveterol

    go.drugbank.com/drugs/DB05043
    Investigational

    GSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.

  10. Drug

    Cannabinor

    go.drugbank.com/drugs/DB05048
    Experimental

    Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.